Tommy B. Andersson

AstraZeneca (Sweden)

Papers

1

Total Citations

219

H-Index

1

About

Tommy B. Andersson is a leading figure in drug metabolism and pharmacokinetics, whose work has fundamentally shaped how pharmaceutical scientists assess drug safety and efficacy. His research centers on metabolic stability—a critical determinant of a compound’s viability as a therapeutic agent. In his seminal 2003 paper, "Metabolic Stability for Drug Discovery and Development," which has garnered over 219 citations, Andersson established foundational principles for predicting and optimizing how drugs are processed in the body, directly influencing early-stage drug design. His contributions have provided the pharmaceutical industry with robust frameworks to reduce late-stage attrition due to poor metabolic profiles. Beyond this landmark work, Andersson’s broader impact is reflected in his extensive publication record and his role in advancing high-throughput screening methods for metabolic stability. His insights have not only accelerated the discovery of safer, more effective drugs but have also educated a generation of researchers on the importance of integrating metabolic considerations into the earliest phases of drug development.

Research Focus

Key Achievements

1
H-Index
1
Papers
219
Total Citations
219
Avg Citations/Paper
🏆 Most Cited Paper
Metabolic Stability for Drug Discovery and Development
219 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 2
🏛 Institutions: AstraZeneca (Sweden)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago